Showing 4411-4420 of 23241 results for "".
You Are What You Eat: How Diet Impacts Cognitive Function & Mood
https://reachmd.com/programs/clinicians-roundtable/you-are-what-you-eat-how-diet-impacts-cognitive-function-mood/13281/We've all heard the phrase "you are what you eat." But are we now at a point where science is backing up that old saying?Another Day in the Frontal Lobe
https://reachmd.com/programs/clinicians-roundtable/another-day-in-the-frontal-lobe/1118/Dr. Katrinia Firlik discusses the writing and publishing of her book, "Another Day in the Frontal Lobe: A Brain Surgeon Exposes Life on the Inside."The Team Approach To Primary Care Medicine
https://reachmd.com/programs/clinicians-roundtable/the-team-approach-to-primary-care-medicine-1/1198/Dr. Michael Greenberg welcomes Dr. Peter Anderson of Newport News, VA, who discusses how a team approach to primary care medicine can help create a more efficient and profitable practice.Sexuality After Cancer
https://reachmd.com/programs/clinicians-roundtable/sexuality-after-cancer/756/Join Dr. Kydd as she discusses intimacy and sexuality after surviving cancer.Clinical Conversations: A conversation with Dr Angela Lamb, a dermatologist and professor in New York, New York
https://reachmd.com/programs/nemluvio-peer-network/clinical-conversations-a-conversation-with-dr-angela-lamb-a-dermatologist-and-professor-in-new-york-new-york/37237/Dr Angela Lamb discusses her approach to treating prurigo nodularis (PN) and atopic dermatitis (AD). She’ll explain how NEMLUVIO®, the first and only neuroimmune-targeted therapy that blocks IL-31RA, targets both immune and neuronal pathways and addresses chronic itch, inflammation, and barrier disrOctane Aesthetics Tech Forum: 2026 to Be Year of Bioregenerative Therapy
https://reachmd.com/conferences/octane-atf-2026/octane-aesthetics-tech-forum-2026-to-be-year-of-bioregenerative-therapy/54703/At the 2026 Octane Aesthetics Tech Forum, Kay Durairaj, MD, founder of Beauty by Dr. Kay, sat down with Modern Aesthetics to discuss how bioregenerative therapies, such as peptides and skin maintenance with collagen stimulators, will take 2026 by storm.Patient Voices in ATTR-CM: Driving Change in Diagnosis, Referral, and Support
https://reachmd.com/programs/on-the-frontlines-of-attr-cm/attr-cm-patient-voices/49033/What do patients with transthyretin amyloid cardiomyopathy (ATTR-CM) really experience during their diagnostic and care journeys? Find out as Dr. Quan Bui joins Ryan Quigley to share findings from in-depth patient interviews spotlighting delayed diagnoses, disparities in access, and the complexAssessing the Role of Metabolic Factors in Psoriasis Management
https://reachmd.com/programs/Audioabstracts/metabolic-factors-psoriasis-management/39678/Emerging research highlights a stronger-than-expected connection between body composition and psoriasis outcome, with a large real-world study examining how body mass index, basal metabolic rate, body surface area, and body weight impact both disease severity and biologic treatment response. Tune inThe Future of Precision Medicine in COPD Care: Biomarkers, AI, and Multimodal Data
https://reachmd.com/programs/frontlines-copd/the-future-of-precision-medicine-in-copd-care-biomarkers-ai-and-multimodal-data/36471/Precision medicine in chronic obstructive pulmonary disease (COPD) care is no longer a distant goal; it’s already taking shape through examples like using eosinophil counts to guide dupilumab therapy. But as Dr. Matthew Moll explains, this is just the beginning. Tune in to hear Dr. Moll talk about hPreventing Osteoporosis with Hormone Therapy: How to Select Appropriate Patients
https://reachmd.com/programs/frontlines-osteoporosis/preventing-osteoporosis-with-hormone-therapy-how-to-select-appropriate-patients/32331/Here are the key factors to consider when determining if a postmenopausal patient at risk of osteoporosis is an appropriate candidate for hormone therapy.